Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the <scp>DELIVER</scp> trial

2021314 citationsJournal Articlebronze Open Access

Authors

Scott D. Solomon · Harvard University

Rudolf A. de Boer · University of Groningen

David L. DeMets · University of Wisconsin–Madison

Adrian F. Hernandez · Duke Medical Center

Silvio E. Inzucchi · Yale University

Mikhail Kosiborod · Saint Luke's Hospital

Carolyn S.P. Lam ·

Abstract

DELIVER will determine the efficacy and safety of the SGLT2 inhibitor dapagliflozin, added to conventional therapy, in patients with heart failure and preserved and mildly reduced ejection fraction.

Topics & Keywords

Diabetes Treatment and Management Heart Failure Treatment and Management Cardiovascular Function and Risk Factors

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: European Journal of Heart Failure

Volume 23, Issue 7, pp. 1217-1225

DOI: 10.1002/ejhf.2249

Field-Weighted Citation Impact: 38.79